# Weight Loss Surgeries Decline as GLP-1 Use Skyrockets
Bariatric surgery referrals have dropped sharply as more families turn to GLP-1 receptor agonist medications like semaglutide (Ozempic, Wegovy) and tirzepatide (Zepbound, Mounjaro) for weight management. This shift reflects a major change in how doctors and patients approach obesity treatment.
GLP-1 drugs work by mimicking a hormone that regulates appetite and blood sugar. They've become increasingly popular because they're less invasive than surgery, deliver results relatively quickly, and don't require recovery time. Patients inject these medications weekly, and many see weight loss within weeks to months.
The decline in bariatric surgeries matters for families considering their options. Surgery remains valuable for people with severe obesity or those who don't respond to medication alone. Gastric bypass and gastric sleeve procedures produce dramatic, lasting weight loss. They work by changing the stomach's size or how the body absorbs food. But they carry surgical risks, require lifestyle changes, and involve potential complications like nutritional deficiencies.
GLP-1 medications offer a reversible alternative that appeals to many families. Unlike surgery, you can stop taking them if side effects develop. Cost remains a barrier, though. Insurance coverage varies. Some plans cover these drugs only for people with type 2 diabetes, not for weight loss alone. Out-of-pocket costs run $900 to $1,500 monthly.
Parents considering weight loss options for their teens or themselves should discuss both approaches with their doctor. GLP-1 drugs work best when combined with diet and exercise changes. They're not magic. Some people regain weight after stopping the medication. Surgical candidates typically need to show they've tried other treatments first.
The conversation with your pediat